Valuation: Quanterix Corporation

Market Cap 137M 123M 113M 103M 192M 12.98B 194M 1.36B 539M 6.8B 513M 502M 21.58B P/E 2026 *
-1.48x
P/E 2027 * -2.34x
Enterprise Value 137M 123M 113M 103M 192M 12.98B 194M 1.36B 539M 6.8B 513M 502M 21.58B EV / Sales 2026 *
0.95x
EV / Sales 2027 * 0.87x
Free-Float
93.63%
Yield 2026 *
-
Yield 2027 * -
10-07 ALZpath, Inc. and Quanterix Corporation Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research CI
10-07 Quanterix Corporation And Innovita Biological Technology Co., Ltd. Receive National Medical Products Administration Approvals For Quanterix SIMOA® Instruments And Neurology Biomarker Testing Kits In China CI
09-25 Quanterix Corporation Launches PhenoCode 2.0 Molecular Barcoding Kit, Confirms TIME And High-Plex ADC Panels For Fourth Quarter Shipment, And Opens Custom ADC Panel Development CI
09-14 Quanterix Corporation Announces Appointment of Dr. Yuri Fesko to Chief Medical Officer CI
08-14 Quanterix Insider Bought Shares Worth $286,354, According to a Recent SEC Filing MT
08-10 Quanterix Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-10 Quanterix Corporation, Q2 2026 Earnings Call, Aug 10, 2026
08-10 Quanterix Corporation Revises Financial Guidance for the Year 2026 CI
08-10 Quanterix Corporation Provides Financial Guidance for the Third Quarter of 2026 CI
08-10 Quanterix Corporation Announces Appointment of Jim Gute as Chief Commercial Officer CI
07-14 Quanterix Advances Adoption of LucentAD Complete Blood Test MT
07-14 Quanterix Announces Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD Complete and Presents New Data Highlighting Multi-Analyte Advantages CI
06-29 Quanterix Corporation(NasdaqGM:QTRX) dropped from Russell Small Cap Comp Growth Benchmark CI
1 day+4.84%
1 week+8.78%
Current month-18.19%
1 month-13.78%
3 months-13.04%
6 months-9.13%
Current year-52.28%
1 week 2.71
Extreme 2.71
3.05
1 month 2.68
Extreme 2.675
3.98
Current year 2.15
Extreme 2.15
8.77
1 year 2.15
Extreme 2.15
8.77
3 years 2.15
Extreme 2.15
29.7
5 years 2.15
Extreme 2.15
60.92
10 years 2.15
Extreme 2.15
92.57
Manager TitleAgeSince
Chief Executive Officer 59 18/01/2026
Director of Finance/CFO 50 21/06/2026
Chief Tech/Sci/R&D Officer - 31/08/2026
Director TitleAgeSince
Director/Board Member 63 05/06/2022
Chairman 64 23/03/2025
Director/Board Member 48 18/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Exercice

Chief Technology Officer

3,583 0.0077%
02/10/26 Exercice

Director

8,448 0.0182%
01/10/26 Free

Director

4,398 0.0095%
Change 5-day change 1-year change 3-year change Capi.($)
+4.84%+8.78%-44.62%-85.25% 137M
+1.27%+1.09%+25.82%+61.62% 256B
+0.96%+0.21%+8.05%+26.61% 163B
+0.03%+4.47%-18.00%+73.02% 155B
-4.52%-3.30%-57.37%-14.01% 65.3B
+0.53%+3.52%+11.34%+46.74% 52.35B
+1.72%+2.11%-12.83%-6.95% 51.93B
+0.75%-1.52%+8.35%+65.91% 50.75B
+1.88%+1.95%+24.24%+79.11% 50.04B
+1.99%+4.52%+38.22%+102.02% 46.03B
Average +0.96%+2.19%-1.68%+34.88% 89.06B
Weighted average by Cap. +0.61%+1.68%+5.30%+50.06%

Financials

2026 *2027 *
Net sales 143M 129M 119M 108M 201M 13.62B 204M 1.42B 566M 7.14B 538M 527M 22.63B 158M 141M 131M 118M 221M 14.97B 224M 1.57B 622M 7.85B 592M 579M 24.89B
Net income -87.98M -78.96M -72.91M -66.12M -124M -8.36B -125M -874M -347M -4.38B -330M -323M -13.89B -82.03M -73.62M -67.98M -61.64M -115M -7.79B -117M -815M -324M -4.08B -308M -301M -12.95B
Net Debt - -
Projected Income Statement - Annual - Quanterix Corporation
Logo Quanterix Corporation
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Employees
450
Date Price Change Volume
28/10/26 US$3.030 +4.84% 289,483
27/10/26 US$2.890 +2.12% 467,696
26/10/26 US$2.830 -1.05% 257,077
23/10/26 US$2.860 +0.70% 349,796
22/10/26 US$2.840 +1.79% 496,285
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Quanterix Corporation
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
2.890USD
Average target price
3.167USD
Spread / Average Target
+9.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Quanterix Corporation
  1. Stock Market
  2. Stocks
  3. QTRX Stock